Difference between revisions of "Thyroid cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replace - "content property of HemOnc.org" to "content property of [http://hemonc.org HemOnc.org]")
m
 
(183 intermediate revisions by 6 users not shown)
Line 1: Line 1:
−
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].'''
+
<span id="BackToTop"></span>
−
 
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
−
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
+
[[#top|Back to Top]]
−
 
+
</div>
 +
{{#lst:Editorial board transclusions|endo}}
 +
<big>'''Note: most thyroid cancer regimens can be found on dedicated pages:
 +
*'''Histology-specific:'''
 +
**'''[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]]
 +
**'''[[Thyroid cancer, medullary|Medullary thyroid cancer]]
 +
*'''Biomarker-specific:'''
 +
**'''[[Thyroid_cancer,_BRAF-mutated|BRAF-mutated thyroid cancer]]
 +
**'''[[Thyroid_cancer,_RET-positive|RET-positive thyroid cancer]]
 +
</big>
 +
{| class="wikitable" style="float:right; margin-right: 5px;"
 +
|-
 +
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
 +
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 +
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 +
=Guidelines=
 +
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 +
==[https://www.thyroid.org/ ATA]==
 +
*'''2015:''' Guidelines on the management of thyroid nodules and differentiated thyroid cancer [https://pubmed.ncbi.nlm.nih.gov/28114862/ PubMed]
 +
*'''2015:''' Guidelines for the management of medullary thyroid carcinoma [https://pubmed.ncbi.nlm.nih.gov/27118126/ PubMed]
 +
*'''2012:''' Guidelines for management of patients with anaplastic thyroid cancer [https://pubmed.ncbi.nlm.nih.gov/23130564/ PubMed]
 +
==[https://www.esmo.org/ ESMO]==
 +
*'''2019:''' Filetti et al. [https://doi.org/10.1093/annonc/mdz400 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/31549998 PubMed]
 +
**'''2012:''' Pacini et al. [https://doi.org/10.1093/annonc/mds230 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/22997443/ PubMed]
 +
**'''2010:''' Pacini et al. [https://doi.org/10.1093/annonc/mdq190 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555084/ PubMed]
  
−
=Medullary thyroid cancer=
+
==NCCN==
−
==Sorafenib (Nexavar)==
+
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470 NCCN Guidelines - Thyroid Carcinoma]
−
===Regimen===
+
**'''2015:''' Haddad et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4986600/ Anaplastic Thyroid Carcinoma, Version 2.2015] [https://pubmed.ncbi.nlm.nih.gov/26358798/ PubMed]
−
*[[Sorafenib (Nexavar)]] 400 mg PO BID
+
**'''2014:''' Tuttle et al. [https://doi.org/10.6004/jnccn.2014.0169 Thyroid Carcinoma, Version 2.2014] [https://pubmed.ncbi.nlm.nih.gov/25505208/ PubMed]
−
 
+
**'''2010:''' Tuttle et al. [https://doi.org/10.6004/Jnccn.2010.0093 Thyroid carcinoma.] [https://pubmed.ncbi.nlm.nih.gov/21081783/ PubMed]
−
===References===
+
**'''2007:''' Sherman et al. [https://doi.org/10.6004/Jnccn.2007.0052 Thyroid carcinoma.] [https://pubmed.ncbi.nlm.nih.gov/17623612/ PubMed]
−
# Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010 May 10;28(14):2323-30. Epub 2010 Apr 5. [http://jco.ascopubs.org/content/28/14/2323.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20368568 PubMed]
+
**'''2005:''' Sherman et al. [https://doi.org/10.6004/Jnccn.2005.0021 Thyroid carcinoma.] [https://pubmed.ncbi.nlm.nih.gov/16002006/ PubMed]
−
 
 
−
==Sunitinib (Sutent)==
 
−
===Regimen===
 
−
*[[Sunitinib (Sutent)]] 37.5 mg PO daily
 
−
 
 
−
===References===
 
−
# Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. [http://clincancerres.aacrjournals.org/content/16/21/5260.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20847059 PubMed]
 
−
 
 
−
==Vandetanib (Caprelsa)==
 
−
===Regimen #1, Wells, et al. 2010 & Wells, et al. 2012===
 
−
*[[Vandetanib (Caprelsa)]] 300 mg PO daily
 
−
 
 
−
===Regimen #2, Robinson, et al. 2010===
 
−
*[[Vandetanib (Caprelsa)]] 300 mg PO daily
 
  
 +
=Advanced or metastatic disease=
 +
==Axitinib monotherapy {{#subobject:73fcb6|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:aff447|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859206/ Cohen et al. 2008 (A4061014)]
 +
|NR
 +
| style="background-color:#91cf61" |Phase 2
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Targeted therapy====
 +
*[[Axitinib (Inlyta)]] 5 mg PO twice per day
 +
'''Continued indefinitely'''
 +
</div></div>
 
===References===
 
===References===
−
# Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010 Feb 10;28(5):767-72. Epub 2010 Jan 11. [http://jco.ascopubs.org/content/28/5/767.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20065189 PubMed]
+
# '''A4061014:''' Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. [https://doi.org/10.1200/jco.2007.15.9566 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859206/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18541897/ PubMed] [https://clinicaltrials.gov/study/NCT00094055 NCT00094055]
−
# Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. Epub 2010 Apr 6. [http://jcem.endojournals.org/content/95/6/2664.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20371662 PubMed] content property of [http://hemonc.org HemOnc.org]  
+
## '''Update:''' Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. Epub 2014 Oct 15. [https://doi.org/10.1007/s00280-014-2604-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236619/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25315258/ PubMed]
−
# Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. Epub 2011 Oct 24. [http://jco.ascopubs.org/content/30/2/134.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22025146 PubMed]
 
−
 
 
−
=Various histologies=
 
−
==Axitinib (Inlyta)==
 
−
===Regimen===
 
−
*[[Axitinib (Inlyta)]] 5 mg PO BID
 
  
 +
==Doxorubicin monotherapy {{#subobject:41edd3|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#ee6b6e">
 +
===Regimen {{#subobject:1efbde|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://doi.org/10.1056/NEJM197401242900404 Gottlieb et al. 1974]
 +
|1971-01 to 1973-06
 +
| style="background-color:#91cf61" |Non-randomized
 +
|-
 +
|}
 +
''Note: This is of historic interest.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Doxorubicin (Adriamycin)]]
 +
</div></div>
 
===References===
 
===References===
−
# Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. [http://jco.ascopubs.org/content/26/29/4708.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18541897 PubMed]
+
# Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin: experience with 30 patients. N Engl J Med. 1974 Jan 24;290(4):193-7. [https://doi.org/10.1056/NEJM197401242900404 link to original article] [https://pubmed.ncbi.nlm.nih.gov/4808917/ PubMed]
−
 
 
−
==Sorafenib (Nexavar)==
 
−
===Regimen===
 
−
*[[Sorafenib (Nexavar)]] 400 mg PO BID
 
−
 
 
−
===References===
 
−
# Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10;26(29):4714-9. Epub 2008 Jun 9. [http://jco.ascopubs.org/content/26/29/4714.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18541894 PubMed]
 
−
 
 
−
==Sunitinib (Sutent)==
 
−
===Regimen===
 
−
*[[Sunitinib (Sutent)]] 37.5 mg PO daily
 
  
 +
==Sorafenib monotherapy {{#subobject:31cae2|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:e09f77|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 80%; text-align:center;"
 +
!style="width: 25%"|Study
 +
!style="width: 25%"|Dates of enrollment
 +
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653134/ Gupta-Abramson et al. 2008]
 +
|2006-02-28 to 2007-09-13
 +
| style="background-color:#91cf61" |Phase 2
 +
|ORR: 23% (95% CI, 10-42)
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Targeted therapy====
 +
*[[Sorafenib (Nexavar)]] 400 mg PO twice per day on days 1 to 28
 +
'''28-day cycles'''
 +
</div></div>
 
===References===
 
===References===
−
# Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. Epub 2010 Sep 16. [http://clincancerres.aacrjournals.org/content/16/21/5260.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20847059 PubMed]
+
# Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10;26(29):4714-9. Epub 2008 Jun 9. [https://doi.org/10.1200/jco.2008.16.3279 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653134/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18541894/ PubMed]
 +
[[Category:Thyroid cancer regimens]]
 +
[[Category:Disease-specific pages]]
 +
[[Category:Endocrine cancers]]
 +
[[Category:Head and neck cancers]]

Latest revision as of 22:53, 2 July 2024

Back to Top

Section editor
Unfilled
If you are interested in this role, please contact us at [email protected].

Note: most thyroid cancer regimens can be found on dedicated pages:

3 regimens on this page
3 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ATA

  • 2015: Guidelines on the management of thyroid nodules and differentiated thyroid cancer PubMed
  • 2015: Guidelines for the management of medullary thyroid carcinoma PubMed
  • 2012: Guidelines for management of patients with anaplastic thyroid cancer PubMed

ESMO

NCCN

Advanced or metastatic disease

Axitinib monotherapy

Regimen

Study Dates of enrollment Evidence
Cohen et al. 2008 (A4061014) NR Phase 2

Targeted therapy

Continued indefinitely

References

  1. A4061014: Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00094055
    1. Update: Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. Epub 2014 Oct 15. link to original article link to PMC article PubMed

Doxorubicin monotherapy

Regimen

Study Dates of enrollment Evidence
Gottlieb et al. 1974 1971-01 to 1973-06 Non-randomized

Note: This is of historic interest.

Chemotherapy

References

  1. Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin: experience with 30 patients. N Engl J Med. 1974 Jan 24;290(4):193-7. link to original article PubMed

Sorafenib monotherapy

Regimen

Study Dates of enrollment Evidence Efficacy
Gupta-Abramson et al. 2008 2006-02-28 to 2007-09-13 Phase 2 ORR: 23% (95% CI, 10-42)

Targeted therapy

28-day cycles

References

  1. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10;26(29):4714-9. Epub 2008 Jun 9. link to original article contains dosing details in manuscript link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Thyroid_cancer&oldid=88006"